U.S. Beverage Stock News

NYSE:IOT
NYSE:IOTSoftware

Assessing Samsara (IOT) Valuation After Mixed Share Price Performance And Strong Undervaluation Narrative

Samsara (IOT) is back on investors’ radar after recent share price moves, with the stock showing a mix of short term gains and longer term declines that invite a closer look at fundamentals. See our latest analysis for Samsara. Recent trading has been volatile, with a 7 day share price return of 7.71% and a 30 day share price return of 14.19% contrasting with a 90 day share price decline of 23.02%. The 3 year total shareholder return of 63.64% sits against a 1 year total shareholder return...
NYSE:LEG
NYSE:LEGConsumer Durables

Leggett & Platt (LEG) Valuation Revisited After Recent Share Price Pullback

Leggett & Platt (LEG) has been drawing attention after a difficult stretch for the stock, with negative returns over the past month and past 3 months prompting investors to reassess the furniture components maker. See our latest analysis for Leggett & Platt. At a share price of US$10.21, Leggett & Platt has logged a 19.03% 1 month share price decline and a 7.10% year to date share price fall. However, its 1 year total shareholder return of 31.14% contrasts sharply with much weaker 3 and 5...
NYSE:CAVA
NYSE:CAVAHospitality

CAVA Pushes Into Ohio As Midwest Growth Tests 1,000 Store Goal

CAVA Group (NYSE:CAVA) has opened its first Ohio restaurant in Cincinnati, extending its presence in the Midwest. The company is using its Ohio entry as part of a broader regional build out that supports its goal of reaching 500 locations in the near term. CAVA has outlined a long term ambition to operate 1,000 restaurants across the United States by 2032. CAVA Group, trading at $80.35, is using this Midwest push to grow its national footprint and add new markets beyond its existing core...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress

Harrow (HROW) has been in focus after reporting higher year over year revenue for both Q4 and 2025, outlining 2026 revenue guidance, and advancing its TRIESENCE program into an FDA cleared Phase 3 trial. See our latest analysis for Harrow. Despite the recent earnings beat and TRIESENCE trial update, Harrow’s 30 day share price return of 25.5% and year to date share price return of 28.8% indicate fading short term momentum. However, the five year total shareholder return of about 3.7x points...
NasdaqGS:PECO
NasdaqGS:PECORetail REITs

Assessing Phillips Edison (PECO) Valuation As Shares Trade Near Analyst Targets

Why Phillips Edison (PECO) is on investors’ radar Phillips Edison (PECO) has drawn attention after recent trading, with shares closing at $38.28 and showing mixed short term returns. This has raised questions about how its current valuation lines up with its fundamentals. See our latest analysis for Phillips Edison. While the 1 day and 7 day share price returns for Phillips Edison have been slightly negative, the 90 day share price return of 9.22% and 1 year total shareholder return of 15.26%...
NYSE:PRI
NYSE:PRIInsurance

Primerica Insider Sales Pattern Raises Questions On Growth Story And Value

Primerica (NYSE:PRI) President Peter Schneider recently sold 1,800 shares of company stock. The transaction adds to a pattern of insider sales at Primerica, with no insider purchases reported over the past year. The sale comes with the stock last closing at $249.06, drawing attention to management’s trading activity. For a company like Primerica, where many investors pay close attention to management alignment, repeated insider selling can stand out. The stock last closed at $249.06, with...
NYSE:CWEN.A
NYSE:CWEN.ARenewable Energy

Is Clearway Energy’s (CWEN.A) Share-Class Merger a Quiet Shift in Its Capital Allocation Story?

In March 2026, Clearway Energy, Inc. received board approval to seek shareholder consent to amend its charter and automatically convert each share of its Class A common stock into one share of Class C common stock, consolidating its public equity into a single share class after the 2026 annual meeting. The move is designed to simplify Clearway’s capital structure by eliminating the less liquid Class A line, potentially improving trading liquidity, broadening the investor base, and better...
NYSE:LAZ
NYSE:LAZCapital Markets

Lazard Shares Under Pressure As Liquidity Concerns Contrast With Valuation Upside

JPMorgan Chase has restricted lending to private credit providers after marking down some loans in its own portfolio. Following this move, Lazard (NYSE:LAZ) and other major financial firms have limited redemptions for certain funds to manage liquidity. The actions highlight fresh concerns about liquidity and stability across parts of the financial sector. Lazard, trading at $40.68, is being pulled into a wider industry story as investors react to tighter lending conditions and capped fund...
NYSE:MAC
NYSE:MACRetail REITs

Is Macerich (MAC) Still Attractive After Recent Share Price Weakness And DCF Upside?

If you are wondering whether Macerich at around US$18.66 is offering real value today, or if the easy gains are already on the table, this article will walk through what the current price actually implies. The stock has seen a 5.8% decline over the last 7 days and a 3.7% decline over 30 days, yet it still shows a 0.8% return year to date and an 18.6% return over 1 year, with a very large 3 year return and a 73.9% return over 5 years. Recent moves in Macerich's share price come against a...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

Is GitLab (GTLB) Now Offering A Rare Opportunity After Steep Share Price Slide?

If you are wondering whether GitLab's share price now reflects a fair deal or an overreaction, you are not alone. That is exactly what this article will unpack. GitLab's stock has been under pressure recently, with a 10.1% decline over the last week, a 27.7% decline over the last month, a 36.9% decline year to date, and a 54.3% decline over the past year. These moves have kept GitLab on many investors' watchlists, as the company remains a key name in DevOps and cloud based software...
NYSE:SWK
NYSE:SWKMachinery

Stanley Black And Decker Governance Vote Tests Confidence In Leadership Structure

A shareholder proposal is asking Stanley Black & Decker to permanently separate the CEO and Chairman roles. The company has recommended that investors vote against the proposal at its upcoming annual meeting. The debate focuses on board oversight, leadership structure, and how power is balanced at NYSE:SWK. For investors following NYSE:SWK, this governance dispute comes as the stock trades at $71.09, with a 5 year return of a 57.2% decline and a 30 day return of a 22.5% decline. Over the...
NYSE:WGO
NYSE:WGOAuto

Is Winnebago Industries (WGO) Now Attractive After Recent Share Price Slide

If you are wondering whether Winnebago Industries at around US$33.45 is a bargain or a value trap, you are not alone. This article focuses squarely on what the current price might be telling you. The stock has been under pressure recently, with a 12.1% decline over the last week and a 29.1% decline over the past month, while the 1 year return sits at 0.7% and the 5 year return at a 55.4% decline. Recent attention around Winnebago has focused on how demand for recreational vehicles fits into...
NYSE:FERG
NYSE:FERGTrade Distributors

A Look At Ferguson Enterprises (FERG) Valuation After Strong Results And Cautious 2026 Outlook

Ferguson Enterprises (FERG) opened down 3.05% on March 9 after releasing strong results and positive 2026 guidance, as investors focused on weaker U.S. residential trends and a 1% decline in HVAC revenues. See our latest analysis for Ferguson Enterprises. That 5.14% one day share price decline, together with a 16.73% 30 day share price return, points to fading short term momentum. However, the 44.60% one year total shareholder return remains strong. If Ferguson’s latest move has you...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia

BioMarin Pharmaceutical (NasdaqGS:BMRN) reported new multi year data on VOXZOGO in young children with achondroplasia. The results, from clinical and real world studies, indicate durable gains in skeletal growth and body proportionality when treatment begins before age 2. The data set is being presented at a major clinical genetics conference, highlighting its relevance for both clinicians and patient communities. BioMarin focuses on therapies for rare genetic conditions, and VOXZOGO is a...
NasdaqGS:FROG
NasdaqGS:FROGSoftware

The Bull Case For JFrog (FROG) Could Change Following Efficient ARR And Cash Generation Metrics – Learn Why

In its most recent quarterly update, JFrog reported annual recurring revenue of US$580.4 million, solid customer acquisition efficiency with a roughly 30‑month payback period, and a strong average free cash flow margin over the past year. This combination of recurring revenue growth, disciplined customer acquisition, and substantial free cash generation underscores a business model geared toward self-funded product and platform investment. Next, we will examine how JFrog’s efficient customer...
NYSE:PG
NYSE:PGHousehold Products

Procter & Gamble’s Gillette Bet Reshapes Grooming Investment Story

Procter & Gamble, ticker NYSE:PG, plans to invest nearly $1b in a new Gillette global headquarters and technical innovation center in Boston. The project will consolidate research, engineering, and business operations for Gillette into a single advanced facility. The investment reflects a long term commitment to the Gillette brand and to Boston’s research and manufacturing ecosystem. For investors watching NYSE:PG, this move comes with the stock trading around $150.5 per share. Over the...
NYSE:EOG
NYSE:EOGOil and Gas

EOG Resources’ US$5.6b Utica Deal Reshapes Growth And Gas Exposure

EOG Resources (NYSE:EOG) agreed to acquire Encino Acquisition Partners for US$5.6b. The deal expands EOG's operational presence in the Utica Shale basin. The transaction is expected to reshape EOG's production profile and capital allocation priorities over time. EOG Resources is a large independent oil and gas producer with a focus on U.S. shale assets, and the Encino Acquisition Partners deal adds another meaningful position in the Utica Shale. For you as an investor, this kind of...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

Is It Time To Reassess Zions Bancorporation (ZION) After The Recent Share Price Pullback

Wondering if Zions Bancorporation National Association is offering good value at its current price, or if the easy money has already been made? The stock last closed at US$54.24, with a 7 day return of a 5.6% decline and a 30 day return of a 15.4% decline, set against a 1 year return of 19.3% and a 3 year return of 90.0%. Recent coverage has focused on how regional banks are being reassessed by investors, with Zions often cited in discussions about balance sheet strength and interest rate...
NYSE:KO
NYSE:KOBeverage

Is Coca-Cola (KO) Still Attractively Priced After Multi Year Share Price Gains

If you are wondering whether Coca-Cola is fairly priced or if the recent share price leaves some value on the table, this article will walk you through what the numbers are actually saying about the stock. The share price recently closed at US$77.61, with returns of 0.8% over 7 days, 1.0% over 30 days, 12.3% year to date, 15.6% over 1 year, 40.7% over 3 years and 78.1% over 5 years. These figures give useful context before comparing that price to different valuation estimates. Recent...
NYSE:ORCL
NYSE:ORCLSoftware

Oracle (ORCL) Earnings Margin Hits 25.3% And Tests Bullish AI Cloud Narratives

Oracle (ORCL) just posted its Q3 2026 numbers, with revenue of US$17.2b and basic EPS of US$1.29, anchored by trailing 12 month EPS of US$5.69 on revenue of US$64.1b. Over recent periods, the company has seen revenue move from US$14.1b in Q3 2025 to US$17.2b in Q3 2026, while quarterly basic EPS shifted from US$1.05 to US$1.29, setting up a story where expanding trailing net profit margins are front and center for investors assessing the quality of these results. See our full analysis for...
NYSE:RTX
NYSE:RTXAerospace & Defense

Is RTX (RTX) Pricing Look Stretched After Strong Multi Year Share Price Run

If you are wondering whether RTX is reasonably priced after its recent run, this article will walk through what the current share price might be implying about the company’s value. RTX last closed at US$203.04, with a 7 day return of a 0.4% decline, 30 day return of 4.0%, year to date return of 8.4%, 1 year return of 59.8% and a 3 year return of 121.0%. This naturally raises questions about how much optimism or risk is now baked into the stock. Recent moves in RTX have played out against a...
NYSE:BFH
NYSE:BFHConsumer Finance

Bread Financial Ford Partnership Adds New Angle To Valuation Story

Bread Financial Holdings (NYSE:BFH) has entered a new long term partnership with Ford Motor Company. The companies plan to launch a co branded credit card and installment loan program tied to Ford's nationwide dealership network. The agreement introduces Ford as a major automotive partner for Bread Financial's payment and lending solutions. Bread Financial focuses on private label and co branded credit cards, installment loans, and related payment products. By teaming up with Ford, NYSE:BFH...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Is It Time To Reconsider Monster Beverage (MNST) After Recent Valuation Concerns

If you are wondering whether Monster Beverage shares still offer value at current levels, this article will walk through what the numbers actually say about the stock. The share price recently closed at US$76.99, with returns of 0.4% over 7 days, a 4.0% decline over 30 days, 1.1% year to date, 41.7% over 1 year and 48.9% over 3 years, while the 5 year return stands at 75.1%. Recent news coverage around Monster Beverage has put more attention on how the company is positioned in the energy...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data

Dyne Therapeutics (DYN) is back in focus after the company kicked off its Phase 3 HARMONIA trial for zeleciment basivarsen in myotonic dystrophy type 1, alongside fresh long term data from its Duchenne program. See our latest analysis for Dyne Therapeutics. Dyne Therapeutics’ recent HARMONIA Phase 3 launch and fresh DELIVER data arrive after a volatile stretch, with a 7 day share price return of 18.82% and a 1 year total shareholder return of 52.02%. This suggests momentum has recently picked...